Profile data is unavailable for this security.
About the company
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. It has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. It offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. It offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.
- Revenue in USD (TTM)312.97m
- Net income in USD-208.73m
- Incorporated2013
- Employees923.00
- LocationTwist Bioscience Corp681 Gateway Blvd.SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (408) 410-0105
- Fax+1 (302) 531-3150
- Websitehttps://www.twistbioscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunocore Holdings PLC - ADR | 296.55m | -47.11m | 1.62bn | 497.00 | -- | 4.27 | -- | 5.45 | -0.9494 | -0.9494 | 5.88 | 7.55 | 0.3593 | 0.541 | 5.68 | 596,681.90 | -5.71 | -27.55 | -7.45 | -36.82 | 99.38 | -- | -15.89 | -97.12 | 3.76 | -- | 0.5373 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Tarsus Pharmaceuticals Inc | 129.62m | -134.34m | 1.84bn | 244.00 | -- | 7.76 | -- | 14.16 | -3.76 | -3.76 | 3.58 | 6.22 | 0.4022 | 6.37 | 7.51 | 531,233.60 | -41.68 | -31.56 | -48.37 | -33.82 | 92.97 | -- | -103.64 | -242.59 | 5.38 | -- | 0.2319 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Endo Inc | -100.00bn | -100.00bn | 1.87bn | 3.00k | -- | 1.02 | -- | -- | -- | -- | -- | 23.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.52 | -- | 0.5697 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Harmony Biosciences Holdings Inc | 681.88m | 122.63m | 1.94bn | 246.00 | 16.13 | 3.26 | 13.23 | 2.85 | 2.11 | 2.11 | 11.75 | 10.46 | 0.7994 | 24.26 | 9.17 | 2,771,866.00 | 14.38 | 7.46 | 17.12 | 9.08 | 78.65 | 80.58 | 17.98 | 10.46 | 3.20 | -- | 0.2345 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Supernus Pharmaceuticals Inc | 651.97m | 59.71m | 2.00bn | 652.00 | 33.91 | 1.99 | 13.99 | 3.07 | 1.07 | 1.07 | 11.71 | 18.24 | 0.4962 | 0.9689 | 4.54 | 999,957.10 | 4.54 | 4.95 | 5.83 | 6.41 | 89.04 | 88.61 | 9.16 | 12.84 | 1.98 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Amphastar Pharmaceuticals Inc | 723.55m | 157.72m | 2.20bn | 1.76k | 15.13 | 3.02 | 10.41 | 3.04 | 3.01 | 3.01 | 13.79 | 15.04 | 0.4684 | 2.83 | 5.60 | 410,873.90 | 10.28 | 9.42 | 11.88 | 11.56 | 52.98 | 47.83 | 21.95 | 15.23 | 2.61 | 9.42 | 0.4506 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Ligand Pharmaceuticals Inc | 152.42m | 45.24m | 2.25bn | 58.00 | 49.12 | 2.66 | 27.88 | 14.78 | 2.43 | 2.43 | 8.25 | 44.84 | 0.1768 | 0.4689 | 4.34 | 2,627,966.00 | 5.25 | 12.32 | 5.37 | 12.99 | 93.52 | 81.65 | 29.68 | 80.32 | 11.81 | -- | 0.00003 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Twist Bioscience Corp | 312.97m | -208.73m | 2.51bn | 923.00 | -- | 5.26 | -- | 8.01 | -3.60 | -3.60 | 5.39 | 8.03 | 0.4501 | 6.40 | 7.93 | 339,083.40 | -30.02 | -28.50 | -33.49 | -31.56 | 42.61 | 39.40 | -66.69 | -93.82 | 4.54 | -- | 0.00 | -- | 27.69 | 41.91 | -2.01 | -- | -19.22 | -- |
| Catalyst Pharmaceuticals Inc | 460.48m | 142.80m | 2.56bn | 167.00 | 18.33 | 3.88 | 14.21 | 5.56 | 1.17 | 1.17 | 3.78 | 5.54 | 0.777 | 4.34 | 8.66 | 2,757,377.00 | 24.10 | 25.42 | 27.94 | 29.81 | 86.32 | 85.63 | 31.01 | 30.87 | 4.92 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Amneal Pharmaceuticals Inc | 2.68bn | -184.45m | 2.60bn | 7.70k | -- | -- | 32.26 | 0.9689 | -0.6835 | -0.6835 | 9.08 | -0.3016 | 0.75 | 2.96 | 3.73 | 348,106.50 | -4.10 | -4.80 | -5.45 | -5.93 | 35.34 | 34.76 | -5.46 | -9.00 | 0.8372 | 1.26 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Vericel Corp | 226.84m | 3.55m | 2.92bn | 314.00 | 764.09 | 11.31 | 327.93 | 12.86 | 0.0774 | 0.0774 | 4.69 | 5.23 | 0.6403 | 4.56 | 5.14 | 722,433.10 | 1.00 | -3.07 | 1.12 | -3.50 | 71.47 | 67.87 | 1.56 | -4.49 | 4.23 | -- | 0.0009 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| PTC Therapeutics, Inc. | 900.66m | -453.20m | 3.33bn | 988.00 | -- | -- | -- | 3.70 | -5.94 | -5.94 | 11.79 | -13.70 | 0.5807 | 1.97 | 4.93 | 911,603.30 | -29.22 | -26.71 | -45.34 | -33.46 | 92.20 | 93.94 | -50.32 | -83.80 | 2.04 | -0.7925 | 1.79 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
Data as of Nov 22 2024. Currency figures normalised to Twist Bioscience Corp's reporting currency: US Dollar USD
66.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Artisan Partners LPas of 30 Sep 2024 | 6.02m | 10.27% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.44m | 9.29% |
| ARK Investment Management LLCas of 30 Sep 2024 | 5.36m | 9.15% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 4.50m | 7.68% |
| William Blair Investment Management LLCas of 30 Sep 2024 | 3.56m | 6.08% |
| Invesco Advisers, Inc.as of 30 Sep 2024 | 3.48m | 5.94% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 3.17m | 5.41% |
| Nikko Asset Management Co., Ltd.as of 30 Sep 2024 | 2.86m | 4.89% |
| Nikko Asset Management Americas, Inc.as of 30 Sep 2024 | 2.86m | 4.88% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 1.51m | 2.57% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
